Is Thyrocare Technologies Ltd debt-free?

Yes, Thyrocare Technologies Ltd is debt-free with a debt-to-equity ratio of 0.04.

Home

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd Financials

Thyrocare Technologies Ltd Financial Statement

Thyrocare Technologies Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	178.41	156.06	165.17
Operating Expense	118.23	112.30	114.26
Net Profit	21.95	19.10	29.59
Net Profit Margin	12.30	12.24	17.91
Earning Per Share	4.08	3.53	5.59
EBIDTA	48.76	45.94	52.47
Effective Tax Rate	23.98	25.18	24.18

Particulars	Mar 2025
Revenue	178.41
Operating Expense	118.23
Net Profit	21.95
Net Profit Margin	12.30
Earning Per Share	4.08
EBIDTA	48.76
Effective Tax Rate	23.98

Thyrocare Technologies Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Total Revenue Annual	633.10	524.02	486.46
Operating Expenses Annual	446.08	390.14	374.45
Operating Profit Annual	200.36	141.06	117.40
Interest Annual	2.63	3.73	2.25
Depreciation	37.72	31.55	26.56
Net Profit Annual	95.78	71.14	56.97
Tax Annual	55.43	27.08	24.10

Particulars	Mar 2025
Total Revenue Annual	633.10
Operating Expenses Annual	446.08
Operating Profit Annual	200.36
Interest Annual	2.63
Depreciation	37.72
Net Profit Annual	95.78
Tax Annual	55.43

Thyrocare Technologies Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Cash Flow at the Beginning	3.56	12.37	11.50
Cash Flow from Operations	190.76	155.19	120.02
Cash Flow from Investing	-54.70	-80.29	-31.65
Cash Flow from Financing	-124.44	-83.71	-87.50
Cash Flow at the End	15.18	3.56	12.37

Particulars	Mar 2025
Cash Flow at the Beginning	3.56
Cash Flow from Operations	190.76
Cash Flow from Investing	-54.70
Cash Flow from Financing	-124.44
Cash Flow at the End	15.18

Thyrocare Technologies Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
PBDIT Margin (%)	31.73	27.14	24.60
PBIT Margin (%)	24.38	19.67	17.60
PBT Margin (%)	16.62	15.64	13.72
Net PROFIT Margin (%)	15.13	13.58	11.71
Return On Networth / Equity (%)	18.23	13.75	10.94
Return On Networth /Employed (%)	27.26	18.63	15.73
Return On Assets (%)	16.94	12.90	10.42
Total Debt / Equity (X)	0.06	0.06	0.04
Asset Turnover Ratio (%)	1.12	0.95	0.89

Particulars	Mar 2025
PBDIT Margin (%)	31.73
PBIT Margin (%)	24.38
PBT Margin (%)	16.62
Net PROFIT Margin (%)	15.13
Return On Networth / Equity (%)	18.23
Return On Networth /Employed (%)	27.26
Return On Assets (%)	16.94
Total Debt / Equity (X)	0.06
Asset Turnover Ratio (%)	1.12

Thyrocare Technologies Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Fixed Assets Annual	156.59	158.29	155.63
Total Current Assets Annual	298.56	245.65	235.37
Non Current Assets Annual	377.79	374.62	376.50
Total Shareholders Funds Annual	537.10	513.81	521.04
Total Assets Annual	676.35	620.27	611.87

Particulars	Mar 2025
Fixed Assets Annual	156.59
Total Current Assets Annual	298.56
Non Current Assets Annual	377.79
Total Shareholders Funds Annual	537.10
Total Assets Annual	676.35

Thyrocare Technologies Ltd Earning Calls

EPS (INR)

Expected

4.10

Reported

4.17

Surprise

1.71%

Dec 2024

EPS beaten by 1.71%

Sep 2024

EPS beaten by -0.83%

Jun 2024

EPS beaten by -0.99%

Dividend Pages

PE Ratio

FAQS on Thyrocare Technologies Ltd Financials

As of Jul 18, 2025, Thyrocare Technologies Ltd has a market capitalization of 3,604.61 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Thyrocare Technologies Ltd is with a debt-to-equity ratio of 0.04.

In FY 2024 , Thyrocare Technologies Ltd recorded a total revenue of approximately 633.10 Cr marking a significant milestone in the company's financial performance.

Thyrocare Technologies Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.1% annually, respectively..

Thyrocare Technologies Ltd's current PE ratio is 37.63.

Thyrocare Technologies Ltd's ROCE averaged 20.3% from the FY ending March 2023 to 2025, with a median of 18.3%. It peaked at 27.2% in March 2025, reflecting strong capital efficiency over the period..

Thyrocare Technologies Ltd's latest EBIT is Rs. 153.84 Cr, surpassing the average EBIT of Rs. 113.04 Cr over the 5 years..